The company plans to launch on the platform tests for diagnosing sexually transmitted diseases and for distinguishing between viral and bacterial infections.
The agreement, which includes an exclusive provider relationship with Boyce and Bynum's anatomic pathology division in Missouri, deepens Quest's Midwest presence.
The deal will give the central Michigan hospital's patients and providers access to a broader range of testing as well as healthcare data analytics.
The assets include significant genetic data related to women's diseases and degenerative disc disease, which Predictive will use to develop gene-based diagnostics.
The firm's Lab21 division will assume the commercial rights to enzyme immunoassay microtiter plates, and latex agglutination, fluorescence, and rapid lateral flow tests.
The acquisition nets Vela a US manufacturing and R&D site, as well as Great Basin's multiplexing platform and six existing FDA-approved products.
DNA Diagnostics is acquiring all the assets of ContraVac, which markets at-home immunoassays for measuring sperm count.
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.
There were 58 M&A deals in the diagnostics space during the year, paced by Quest, which announced 12 deals. Abbott's $5.3 billion buy of Alere was the biggest acquisition.